Allogene Therapeutics (ALLO) News Today → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free ALLO Stock Alerts $4.47 +0.01 (+0.22%) (As of 05:21 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAllogene Therapeutics (NASDAQ:ALLO) Trading 9% Higher marketbeat.com - March 27 at 4:44 PMAllogene Therapeutics (NASDAQ:ALLO) Given Buy Rating at HC Wainwrightamericanbankingnews.com - March 20 at 5:52 AMStifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)markets.businessinsider.com - March 20 at 5:19 AMAllogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancementsmarkets.businessinsider.com - March 19 at 9:16 AMAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 19 at 8:34 AMAllogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by Royal Bank of Canadaamericanbankingnews.com - March 19 at 3:06 AMAnalysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)markets.businessinsider.com - March 18 at 11:13 PMRoyal Bank of Canada Reiterates Outperform Rating for Allogene Therapeutics (NASDAQ:ALLO)marketbeat.com - March 18 at 3:10 PMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Increase in Short Interestamericanbankingnews.com - March 18 at 7:22 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - March 18 at 2:42 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 18 at 2:39 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 16 at 6:34 PMAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updatefinanznachrichten.de - March 15 at 4:16 PMAllogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel Therapymarkets.businessinsider.com - March 15 at 4:16 PMAllogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value Growthmarkets.businessinsider.com - March 15 at 11:12 AMAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 3.8% on Better-Than-Expected Earningsmarketbeat.com - March 15 at 10:25 AMALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 10:04 PMAllogene Therapeutics files for $500M mixed shelfmsn.com - March 14 at 9:00 PMAllogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updateglobenewswire.com - March 14 at 4:05 PMAllogene Therapeutics (NASDAQ:ALLO) Shares Down 8.2% marketbeat.com - March 14 at 12:47 PMAllogene Therapeutics Q4 2023 Earnings Previewmsn.com - March 13 at 6:33 PMZinc Polycarboxylate Cement Market Size is Anticipated to Reach USD 282.1 million by 2031, with a CAGR of 5.6%. - Transparency Market Research, Inc.finance.yahoo.com - March 13 at 1:33 PMAllogene, Arbor Announce Global Gene Editing Licensing Agreement For CAR T Platformmarkets.businessinsider.com - March 12 at 10:16 AMAllogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Diseaseglobenewswire.com - March 12 at 8:30 AMANTION BIOSCIENCES SA: Antion Biosciences announces latest data and validation of its technology platform through important milestone achievementsfinanznachrichten.de - March 6 at 7:48 PMAllogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Updateglobenewswire.com - March 5 at 8:30 AMCaxton Associates LP Has $1.52 Million Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - February 28 at 3:48 PMAllogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conferenceglobenewswire.com - February 28 at 8:30 AMPrimecap Management Co. CA Lowers Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - February 26 at 8:56 AMALGS Apr 2024 2.500 callca.finance.yahoo.com - February 25 at 10:19 AMAllogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on Mondaymarketbeat.com - February 25 at 7:32 AMAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asiafinance.yahoo.com - February 16 at 8:59 AMAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asiaglobenewswire.com - February 16 at 8:30 AMBarclays PLC Boosts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)marketbeat.com - February 14 at 4:36 AMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Decline in Short Interestmarketbeat.com - February 13 at 8:41 AMQ1 2024 EPS Estimates for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Lifted by Zacks Researchmarketbeat.com - February 8 at 7:30 AMAllogene Therapeutics Inc (ALLO)uk.investing.com - January 30 at 2:23 PMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - January 28 at 2:52 AMDelveInsight Business Research, LLP: CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsightfinanznachrichten.de - January 23 at 5:27 PMAllogene Therapeutics price target lowered by $2 at H.C. Wainwright, here's whyrealmoney.thestreet.com - January 19 at 12:47 PMAllogene Therapeutics (NASDAQ:ALLO) Shares Down 5% After Analyst Downgrademarketbeat.com - January 19 at 12:32 PMAllogene Therapeutics (NASDAQ:ALLO) Price Target Cut to $10.00marketbeat.com - January 19 at 8:15 AMQ1 2024 EPS Estimates for Allogene Therapeutics, Inc. Increased by Zacks Research (NASDAQ:ALLO)marketbeat.com - January 15 at 1:57 AMAllogene Therapeutics: A Promising Biotech With A Concerning Lag Time Aheadseekingalpha.com - January 8 at 12:00 AMJMP Securities Downgrades Allogene Therapeutics (ALLO)msn.com - January 7 at 10:09 AMAllogene drops on layoffs and pipeline reorganization (update)msn.com - January 6 at 10:53 PMGuggenheim Downgrades Allogene Therapeutics (ALLO)msn.com - January 6 at 10:53 PMAllogene cuts 22% of workforce amid blood cancer therapy pivotmsn.com - January 5 at 9:52 PMAllogene Therapeutics shares plunge, company announces 22% workforce reductionin.investing.com - January 5 at 4:51 PMAllogene Therapeutics Shares Fall on Strategy Shift, Job Cutsmarketwatch.com - January 5 at 4:51 PM Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade. Register for the imminent briefing here. ALLO Media Mentions By Week ALLO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼-0.020.60▲Average Medical News Sentiment ALLO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼33▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EXAI News Today CABA News Today FATE News Today NVAX News Today CGEM News Today TRML News Today HLVX News Today EDIT News Today PRME News Today CCCC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.